IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic ...

ATHENS, GEORGIA / ACCESS Newswire / October 21, 2025 / NDT Pharmaceuticals Inc. (OTC PINK:NDTP), a company focused on advancing innovative consumer health and wellness solutions, today announced a ...

Clearance expands Company's competitive advantage of clinically proven, minimally invasive technologies to treat debilitating SI joint conditions from multiple surgical approaches~~SImmetry+'s New 3D ...

Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients with mild to moderate renal impairment, showed the URAT1 inhibitor lowered serum uric ...

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and ...

Clean Jeju Green Tea Cooperative ‘Sumang’, a leading processor of agricultural, marine, and herbal materials from Jeju Island, announced plans to expands its research and development activities of ...

Open-science research initiative, COVID Moonshot and the AI-driven Structure-enabled Antiviral Platform (ASAP) consortium, delivered a promising pre-clinical candidate2,000 new compounds generated for ...

October 21, 2025 - Nanoform Finland Plc (“Nanoform”), a leading nanoparticle medicine performance-enhancing company, today announced that key findings from two proof-of-concept studies conducted in ...

Funds build on close to €30M in legacy support to advance Exeliom’s immunomodulator program, EXL01, addressing cancers, inflammatory and infectious diseases Paris, France, October 21, 2025 — Exeliom ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 monthsCHICAGO, USA and OXFORD, UK October 20th 2025 – ...